FRAZIER LIFESCIENCES ACQUISITION CORPORATION Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.25 EUR | -7.59% |
|
+15.43% | +76.81% |
Presenter SpeechRoanna Clarissa Ruiz (Analysts)Global Biopharma Conference with Leerink. My na...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimerâs disease. The Company strives to offer its products around the world.
Calendar
05/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.49
EUR
Average target price
35.19
EUR
Spread / Average Target
+90.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +76.81% | 177.72Cr | |
| +16.13% | 12TCr | |
| +19.65% | 12TCr | |
| +21.22% | 2.66TCr | |
| -23.84% | 1.99TCr | |
| -17.47% | 1.63TCr | |
| -45.95% | 1.55TCr | |
| -19.28% | 1.55TCr | |
| +63.81% | 1.48TCr | |
| +1.94% | 1.37TCr |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Transcript : NewAmsterdam Pharma Company N.V. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04
